Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Aprea Therapeutics in connection with its listing on Nasdaq, New York
Mandate

Vinge has advised Aprea Therapeutics in connection with its listing on Nasdaq, New York

October 17, 2019 Capital Markets and Public M&A

Vinge has advised Aprea Therapeutics, Inc. and its subsidiary Aprea Therapeutics AB in connection with its listing on Nasdaq, New York.

The initial public offering price was set to $15 and the biopharmaceutical company sold 6.5 million shares in the IPO to raise $97.75 million. Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing cancer therapeutics.

 
Vinge’s team has primarily consisted of Kristina Ekberg, Charlotte Levin, Maria Schultzberg, Anna Thoms and Stina Bengtsson.

Related

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026

Vinge has advised Skeptiva AB in connection with its financing round

 Skeptiva is developing the next generation of cybersecurity defenses against fraud. The company has developed an AI application that detects attacks and alerts users in real time.
March 11, 2026

Vinge has advised Main Capital in connection with the acquisition of Good Solutions Sweden AB

 Good Solutions Sweden AB (”Good Solutions”) provides software that helps factories identify and reduce production losses. The software converts data from machines and operators into insights that can be used to streamline production and increase profitability.
March 11, 2026